Psyence Group Inc. (PSYGF)
USD 0.3
(0.0%)
USD 0.3
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -5.16 Million CAD | 12.11% |
| 2023 | -5.87 Million CAD | -32.03% |
| 2022 | -4.46 Million CAD | -4808.59% |
| 2021 | -3.79 Million CAD | -385.47% |
| 2020 | -19.05 Thousand CAD | 58.41% |
| 2019 | -45.82 Thousand CAD | -129.44% |
| 2018 | -19.97 Thousand CAD | 63.55% |
| 2017 | -54.79 Thousand CAD | -272.97% |
| 2016 | -14.69 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - CAD | 13.9% |
| 2024 Q4 | -1.69 Million CAD | -100.57% |
| 2024 Q3 | -841.93 Thousand CAD | -97.52% |
| 2024 Q2 | -415.54 Thousand CAD | 80.67% |
| 2024 Q1 | -2.21 Million CAD | 20.86% |
| 2023 Q3 | -1.07 Million CAD | -11.13% |
| 2023 Q4 | -2.79 Million CAD | -160.34% |
| 2023 Q1 | -1.16 Million CAD | -10.69% |
| 2023 FY | - CAD | -32.03% |
| 2023 Q2 | -966.11 Thousand CAD | 16.77% |
| 2022 FY | - CAD | -4808.59% |
| 2022 Q3 | -1.2 Million CAD | -8.8% |
| 2022 Q2 | -1.1 Million CAD | 7.15% |
| 2022 Q1 | -1.18 Million CAD | 42.49% |
| 2022 Q4 | -1.04 Million CAD | 12.64% |
| 2021 FY | - CAD | -385.47% |
| 2021 Q4 | -2.06 Million CAD | -2731.32% |
| 2021 Q2 | -7620.00 CAD | -6643.36% |
| 2021 Q3 | -72.98 Thousand CAD | -857.74% |
| 2021 Q1 | -113.00 CAD | 0.0% |
| 2020 FY | - CAD | 58.41% |
| 2019 FY | - CAD | -129.44% |
| 2018 FY | - CAD | 63.55% |
| 2017 FY | - CAD | -272.97% |
| 2016 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | 100.039% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 100.027% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | 100.45% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 86.986% |
| Novartis AG | 19.51 Billion USD | 100.026% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | 101.793% |